Skip to Main Content
Table 1.

In vivo efficacies of PD-0332991, Avastin, and docetaxel in MDA-MB-435-HAL-Luc SRC model

Agent* (dose in mg/kg)% TGI against primary tumor
% Inhibition of lung tumor burden
Median survival (d)
day 46day 63day 46day 63
Vehicle 67.5 
PD-991 (200) 71.2 36.4% 70.4% 51.3% 74.5 
Avastin (15) 68.5§ 75.6 71.4% 81.1%§ 81 
TXT (15) 66.5%§ 83.5%§ 97.1 %§ 94.2%§ 89§ 
TXT (30) 105%§ 98.6%§ 100%§ 99.4%§ 112§ 
Agent* (dose in mg/kg)% TGI against primary tumor
% Inhibition of lung tumor burden
Median survival (d)
day 46day 63day 46day 63
Vehicle 67.5 
PD-991 (200) 71.2 36.4% 70.4% 51.3% 74.5 
Avastin (15) 68.5§ 75.6 71.4% 81.1%§ 81 
TXT (15) 66.5%§ 83.5%§ 97.1 %§ 94.2%§ 89§ 
TXT (30) 105%§ 98.6%§ 100%§ 99.4%§ 112§ 

Abbreviations: TGI, tumor growth inhibition; PD-991, PD-0332991; TXT, docetaxel.

*

PD-0332991 was administered via oral gavages twice each week for 3 wk. Avastin was i.p. administered once each week for 7 wk. Docetaxel was administered via i.p. injection once each week for 2 wk.

%TGI was calculated as 100 x (1-ΔT/ΔC). Changes in tumor volumes (Δ) for each treated (T) and control (C) group were calculated by subtracting the mean tumor volume on the 1st day of treatment from the mean tumor volume at the day of assessment.

P < 0.05 (versus vehicle-treated group by one-way ANOVA followed by Dunnet's t test).

§

P < 0.01 (versus vehicle-treated group by one-way ANOVA followed by Dunnet's t test).

Close Modal

or Create an Account

Close Modal
Close Modal